Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

Blood (2019) 134 (Supplement_1): 2619.

https://doi.org/10.1182/blood-2019-129279

Published: 2019

Journal Articles

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Samantha Jaglowski, MD, Zhen-Huan Hu, MPH, Yiyun Zhang, PhD, Manali Kamdar, MD, Monalisa Ghosh, Premal Lulla, MBBS, Joshua Sasine, MD PhD, Miguel-Angel Perales, MD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Margit Jeschke, PhD, Lan Yi, PhD, Raghav Chawla, MD PhD, Lida Pacaud, Mary M. Horowitz, Eric Bleickardt, MD, Marcelo C. Pasquini, MDMS

Blood (2019) 134 (Supplement_1): 766.

https://doi.org/10.1182/blood-2019-130983

Published: 2019

Journal Articles

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

Blood (2018) 132 (Supplement 1): 895.

https://doi.org/10.1182/blood-2018-99-112599

Published: 2018

Journal Articles

Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients

Blood (2018) 132 (Supplement 1): 899.

https://doi.org/10.1182/blood-2018-99-116385

Published: 2018

Journal Articles

Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel

Blood (2018) 132 (Supplement 1): 1551.

https://doi.org/10.1182/blood-2018-99-115460

Published: 2018

Journal Articles

Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial

Kazuteru Ohashi, Kenshi Suzuki, MD PhD, Kazutaka Sunami, MD PhD, Shinsuke Iida, MD PhD, Shinichiro Okamoto, MD PhD, Hiroshi Handa, MD PhD, Kosei Matsue, MD PhD, Masafumi Miyoshi, Eric Bleickardt, MD, Morio Matsumoto, MD, Masafumi Taniwaki, MD PhD

Blood (2016) 128 (22): 3315.

https://doi.org/10.1182/blood.V128.22.3315.3315

Published: 2016

Journal Articles

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Andrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, Javier De La Rubia, Laurent Garderet, Kamel Laribi, Alberto Bosi, Roberto Marasca, Jacob Laubach, Ann Mohrbacher, Angelo Michele Carella, Anil K. Singhal, L. Claire Tsao, Mark Lynch, Eric Bleickardt, Ying-Ming Jou, Michael Robbins, Antonio Palumbo

Blood (2016) 127 (23): 2833–2840.

https://doi.org/10.1182/blood-2016-01-694604

Published: 2016

Includes: Supplemental data

Journal Articles

Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Paul G. Richardson, Sundar Jagannath, MD, Philippe Moreau, MD, Andrzej Jakubowiak, MD PhD, Marc S Raab, MD PhD, Thierry Facon, MD, Ravi Vij, MD, Darrell White, MD, Donna E. Reece, MD, Lotfi Benboubker, MD PhD, Jeffrey Zonder, MD, L. Claire Tsao, PhD, Kenneth C. Anderson, MD, Eric Bleickardt, MD, Anil K Singhal, MD, Sagar Lonial, MD

Blood (2014) 124 (21): 302.

https://doi.org/10.1182/blood.V124.21.302.302

Published: 2014

Journal Articles

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

Jesus Berdeja, MD, Sundar Jagannath, MD, Jeffrey Zonder, MD, Ashraf Badros, MD, Jonathan L. Kaufman, MD, Robert Manges, MD, Mark Lynch, PhD, Eric Bleickardt, MD, Prashni Paliwal, PhD, Ravi Vij, MD

Blood (2014) 124 (21): 2119.

https://doi.org/10.1182/blood.V124.21.2119.2119

Published: 2014

Journal Articles

Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study.

Thierry Facon, Xavier Leleu, A. Keith Stewart, MD, Andrew Spencer, Philip Rowlings, Cyrille Hulin, Michel Attal, Felix Garzon, MD, PhD, Eric Bleickardt, Konstantina Gialelis, Doreen Tuozzoli, Dominique Derreumaux, Pieter Sonneveld

Blood (2009) 114 (22): 1876.

https://doi.org/10.1182/blood.V114.22.1876.1876

Published: 2009

Journal Articles

Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.

Andreas Hochhaus, MD, Martin C Müller, MD, Jerald Radich, MD, Susan Branford, Benjamin Hanfstein, MD, Philippe Rousselot, MD, PhD, Jeffrey H Lipton, MD, PhD, Eric Bleickardt, Ritwik Sinha, Timothy P Hughes, MD

Blood (2008) 112 (11): 1095.

https://doi.org/10.1182/blood.V112.11.1095.1095

Published: 2008

Journal Articles

Dasatinib Time to and Durability of Major and Complete Cytogenetic Response (MCyR and CCyR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Michele Baccarani, MD, Gianantonio Rosti, Giuseppe Saglio, MD, Jorge Cortes, Richard Stone, Dietger W. Niederwieser, MD, Eric Bleickardt, Ritwik Sinha, Bengt Simonsson

Blood (2008) 112 (11): 450.

https://doi.org/10.1182/blood.V112.11.450.450

Published: 2008

Journal Articles

Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients.

Martin C. Mueller, MD, Philipp Erben, MD, Thomas Ernst, MD, Michelle Giehl, PhD, Thomas Schenk, MD, Jana Hoffmann, Stephanie Lauber, MD, Jens Kruth, MD, Benjamin Hanfstein, MD, Eric Bleickardt, MD, Claude Nicaise, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2007) 110 (11): 319.

https://doi.org/10.1182/blood.V110.11.319.319

Published: 2007

Journal Articles

Long-Term Efficacy of Dasatinib in Chronic-Phase CML: Results from the Phase I Trial (CA180002).

Jorge Cortes, MD, Charles L. Sawyers, MD, Hagop M. Kantarjian, MD, Neil P. Shah, MD, Ronald Paquette, MD, Prashni Paliwal, Eric Bleickardt, MD, Moshe Talpaz, MD

Blood (2007) 110 (11): 1026.

https://doi.org/10.1182/blood.V110.11.1026.1026

Published: 2007

Journal Articles

Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013).

Richard M. Stone, MD, Hagop M. Kantarjian, MD, Michele Baccarani, MD, Jeffrey H. Lipton, MD, Timothy Hughes, MD, Rana Ezzeddine, PhD, Eric Bleickardt, MD, Andreas Hochhaus, MD

Blood (2007) 110 (11): 734.

https://doi.org/10.1182/blood.V110.11.734.734

Published: 2007

Journal Articles

Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017).

Hagop M. Kantarjian, MD, Philippe Rousselot, MD, Ricardo Pasquini, MD, Nelson Hamerschlak, MD, Jerzy Holowiecki, MD, David Dejardin, Eric Bleickardt, MD, Neil P. Shah, MD

Blood (2007) 110 (11): 736.

https://doi.org/10.1182/blood.V110.11.736.736

Published: 2007

Journal Articles

Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development.

Neil P. Shah, MD, PhD, John M. Nicoll, BS, Eric Bleickardt, MD, Claude Nicaise, MD, Ronald L. Paquette, MD, Charles L. Sawyers, MD

Blood (2006) 108 (11): 2166.

https://doi.org/10.1182/blood.V108.11.2166.2166

Published: 2006

Journal Articles

Major Molecular Responses to Dasatinib (BMS-354825) Are Observed in Imatinib-Resistant Late Stage Chronic and Advanced CML Patients: Impact and Fate of Imatinib-Resistant Clones in Dasatinib-Treated Patients.

Susan Branford, Timothy Hughes, John Nicoll, Ron Paquette, Eric Bleickardt, Charles Sawyers, Neil Shah

Blood (2005) 106 (11): 437.

https://doi.org/10.1182/blood.V106.11.437.437

Published: 2005

NARROW

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients

Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel

Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study.

Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.

Dasatinib Time to and Durability of Major and Complete Cytogenetic Response (MCyR and CCyR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients.

Long-Term Efficacy of Dasatinib in Chronic-Phase CML: Results from the Phase I Trial (CA180002).

Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013).

Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017).

Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development.

Major Molecular Responses to Dasatinib (BMS-354825) Are Observed in Imatinib-Resistant Late Stage Chronic and Advanced CML Patients: Impact and Fate of Imatinib-Resistant Clones in Dasatinib-Treated Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only